Similarly, PARP catalytic activity, another pivotal factor of PARP inhibitors’ cytotoxicity [23], was inhibited by olaparib indicated by a robust reduction of PARs compared to controls whereas AZD1775 almost had no impact in GC cells (Additional file 2: Figure S2b). Here, PARP1 is linked to gastric cancer.